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Background: The ‘cohort multiple Randomised Controlled Trial’ (cmRCT) design has been proposed as a potential
solution to poor recruitment into clinical trials. The design randomly selects participants eligible for experimental
treatments from a pre-enrolled cohort of patients, recruiting participants to multiple trials from a single cohort.
Controls remain unaware of their participation in specific trials.
Methods: We undertook a mixed methods study to determine the ethical acceptability, the proportion of
patients in a routine service consenting to cohort participation, the proportion of these who would consent to
being hypothetically randomly selected to receive new treatments, and the views of clinicians on the
acceptability of the design. We submitted our cmRCT design for ethical review and recruited participants from
people with anxiety and depression attending a community mental health service of twenty-one clinicians. We
recorded the proportion of patients who were offered participation in the DiReCT study and the proportion that
consented to researcher contact, medical record sharing, and who accepted to be randomly allocated to active
treatment procedures in future hypothetical unspecified clinical trials. We used a thematic framework analysis to
analyse clinician interviews.
Results: We obtained a favourable ethical opinion from the UK Health Research Authority. Clinicians
approached 131/752 (17%) potentially eligible participants for consent. Of these 131, 84 (64%) initially consented
to be contacted by a researcher and all but one consented to being randomised into future trials. We confirmed
consent for 71 (54%) of participants approached by clinicians, of whom 69 (53%) consented to being
randomised into hypothetical future trials, 9% (69/752) of all potentially eligible patients. The interviewed
clinicians described issues impacting on their ability to recruit participants in terms of clinical concerns for
patient wellbeing, work pressure, their views of both general research and the specific DiReCT study, and how
they viewed patients’ responses to being offered participation in the study.
Conclusions: The cmRCT system offers the potential to improve the recruitment into clinical trials and is
acceptable ethically and to many patients. Overcoming the multiple factors driving the difficulties clinicians
experience in patient recruitment is likely to require the application of significant implementation science-informed
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The randomised controlled trial (RCT) is regarded by
scientists and health commentators alike as the ‘gold
standard’ example [1] of a ‘fair test’ [2] for establishing
the effectiveness of a treatment. Nonetheless, recruit-
ment issues, sampling bias, ethics, patient preferences
and treatment comparisons can limit the application of
the RCT design in practice [3]. For example, many trials
struggle to recruit participants. No more than 50% of tri-
als [4-9] recruit to target or on time, with the conse-
quence that some trials may be underpowered, requiring
further trials and delaying the time when decisions on
whether or not to adopt new interventions can be made.
Recruitment to multiple trials usually requires repetitive
and wasteful investment in participant identification
systems [10]. Patients might decline participation in tri-
als for fear of receiving a treatment they perceive as less
desirable than the alternative or because they reject the
idea of their treatment being allocated by chance [1,11].
In the UK, embedding research in clinical services is a
core function of the National Health Service (NHS). UK
government policy states that every eligible patient at-
tending an NHS treatment programme should be offered
the opportunity to participate in clinical research [12].
Governmental purchasers of health care need to demon-
strate that they have in place systems and processes to
promote the recruitment of patients into research [13].
The National Institute for Health Research (NIHR) in
the UK also recognises the importance of increasing
opportunities for patients and the public to participate
in research to help the NHS become an internationally
recognised centre of research excellence [14,15].
Embedding research into routine clinical practice is
one potential method to improve the recruitment of
participants into clinical trials. Recruitment methods
tailored to routine health delivery systems could avoid
repetitive and expensive procedures, provide efficiencies
of scale and may overcome poor recruitment yields. The
Zelen design [16] was originally proposed as a way of
maximising recruitment into clinical trials by eliminating
the need for clinicians to have pre-consent conversations
with their patients about clinical uncertainty, randomisa-
tion and all treatment options in a trial. In this design,
participants for a trial are identified and randomised
without their knowledge or consent for trial participation.
Consent for subsequent treatment allocation is sought
after the randomisation procedure has been undertaken.
However, despite this method potentially increasing
recruitment, the Zelen design has been argued to be un-
ethical since participants have not been given the opportun-
ity to consent to be involved in a clinical trial before one
important component of that trial has been undertaken –
that is, the random allocation of treatment [17]. Exercising
informed choice as to whether one should be randomlyallocated to receive a treatment or procedure in a clinical
trial is a fundamental principle of ethical research conduct
[18], and one might reasonably argue that this should also
be applied to those participants contributing data having
been randomised or selected to be part of a control group,
not just those allocated to the experimental intervention.
Consequently, a number of modifications to the Zelen
design [16] have been proposed, including the ‘single
consent design’ [17]. In this design, consent for trial par-
ticipation is only sought from participants who have pre-
viously consented to be involved in an observational
study. Subsequently, some participants in the observa-
tional study are then randomised into an experimental
treatment group and specific consent for their participa-
tion in the experimental treatment is sought. No further
consent is sought from participants randomised to the
control condition, who remain unaware of the trial al-
though their data is used to compare the performance of
the experimental treatment against the control. As an
extension of this, Relton and colleagues [3] have pro-
posed the ‘cohort multiple randomised controlled trial’
(cmRCT) design in which multiple trials can be run
from the same cohort using a similar consent procedure
as above, but applied to sub-samples of cohort partici-
pants carefully selected according to different trial inclu-
sion criteria. Neither of these designs seek a priori
consent to be part of an experimental evaluation from
participants randomised to the treatment as usual condi-
tions and neither design provides information about the
trial treatment to people receiving and providing data on
treatment as usual in the trial. The UK Medical Research
Council has recommended considering such ‘non-stand-
ard’ randomised consent designs as a method to over-
come challenges for evaluating complex interventions,
especially if there is a risk of patient preference bias [19].
In the cmRCT design, patients with the condition of
interest are invited to participate in an observational co-
hort and have their routine outcome data collected by
researchers at regular intervals for health research
purposes. Those patients who consent to being in the
cohort essentially become a pool of ‘research-ready’
potential participants for recruiting directly into RCTs. A
key feature of the cmRCT design is how consent is sought
for the randomization process. Eligible participants are
identified from the observational cohort, and then rando-
mised to either the treatment or control group without
prior consent. Consent is only sought from eligible partici-
pants who are selected for the experimental treatment
arm of the trial on whether they wish to accept the trial
treatment or not. The control group consists of cohort
participants who were eligible for the experimental treat-
ment if they had been randomly selected, but these people
are not told that they could have been randomly selected
to receive the experimental intervention, nor that their
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trial. They continue to receive treatment as usual, being
assessed as part of the longitudinal cohort to provide
comparative data. This approach has been described as
random selection of ‘some’ of the cohort rather than
random allocation of ‘all’ of the cohort [3]. The process of
obtaining patient consent from only those selected for the
intervention (the ‘offer’ group) aims to replicate the
process in real world routine health care where clinicians
usually only provide patients with information about their
treatment at a time they need the treatment and when the
treatment is available.
The cmRCT method has yet to be tested fully in terms
of ethical, clinical and patient acceptability, and recruit-
ment efficiency. Relton and colleagues have applied the
cmRCT design with a cohort of women in the meno-
pause which received ethics permission [20]. Kwakkenbos
and colleagues have recently published a protocol to test
the cmRCT method with a rare disease cohort but no
results are as yet available [21]. However, neither of these
studies have tested the acceptability to patients of their
‘potential for randomisation’ – that is, whether patients
would consent to join a cohort on the understanding that
they may be randomly selected to receive experimental
treatments in currently unspecified clinical trials sometime
in the future. As such, therefore, we do not know the ac-
ceptability to patients of the cmRCT design, or the likely
recruitment yield of implementing such a system.
In Relton and colleagues original proposal [3], they
suggested that the cmRCT design be established within
an observational cohort. In our DiReCT – improving re-
cruitment to clinical trials - study not only did we aim
to test the recruitment yield of the cmRCT design but
also the potential for the cmRCT design to contribute to
the embedding of research into routine practice. We
chose a high-volume mental health service as a case
study to determine if patients within a mental health set-
ting would give consent to be part of a cohort when
approached by clinicians. Not only did we want to assess
the feasibility of a system where patients agree to join a
cmRCT cohort within which there is the potential to be
selected to receive treatments being tested in RCTs, we
also wanted to assess the extent to which mental health
clinicians could, or would, undertake cmRCT participant
recruitment.
In our hypothetical cmRCT system, specific treatments
would not be specified at the time of consent to participa-
tion and only those randomly selected to receive experi-
mental treatments would be approached by investigators
with details of the specific trial. Control patients would,
therefore, provide data to the trial(s) but would not be
specifically approached again regarding trial participation.
Participants would always be asked for consent to try an
intervention if they were selected, but those in the controlgroup, who were not selected, would not be given any
information about the trial.
Although there were no actual trials running at the
time of the DiReCT study, we wanted to undertake a
proof of principle study before potentially investing in
setting up the cmRCT cohort. Our study was, therefore,
hypothetical in nature in that we were testing the likeli-
hood of participants consenting to our procedures. We
wished to undertake this feasibility test before using the
cmRCT design to recruit participants into a cohort and
then actual trials, since if the system was implemented
as a means to improve trial recruitment and then proved
unacceptable to participants it could jeopardise the
trials.
Research questions
In the DiReCT study we posed four questions:
1) The ‘Ethics Test’ – how ethically acceptable is the
cmRCT?
2) The ‘Recruitment Test’ – what proportion of NHS
patients with common mental health problems will
agree to join a cmRCT cohort?
3) The ‘Trials Test’ – how many patients in the cohort
would prospectively consent to being randomly
selected to receive new treatments?
4) Clinical acceptability – what were the views of
clinicians about the process of routinely recruiting
patients into a cmRCT?
Methods
Study design
Our design was observational and uncontrolled in na-
ture in that we did not conduct an experimental com-
parison of recruitment methods. We undertook a mixed
methods study to test the feasibility of the cmRCT
method for recruiting participants into a cohort which
could then be used for RCT recruitment. In the first
phase of the DiReCT study we tested the ethical accept-
ability of the cmRCT method; in the second phase we
tested the recruitment yield; and in the third phase we
investigated the views of participating clinicians.
Setting and participants
We conducted the DiReCT study at a single clinical site
in the south of the UK, part of a larger ‘Improving Ac-
cess to Psychological Therapies’ (IAPT) service, treating
people for common mental health problems, such as de-
pression and anxiety. The study site receives over 3,500
patient referrals annually and covers a population radius
of 62 km2. We recruited patients attending the service,
aged 18 and older, during a 4-month period between
November 2012 and February 2013. Patients were those
being assessed and treated for common mental health
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chological Wellbeing Practitioners (PWPs) and senior
therapists – who provided psychological treatment to
patients. We also recruited a purposive sample of cli-
nicians who had been involved in recruiting partici-
pants for the DiReCT study.
Procedures
Phase I: the ethics test
In our first phase we applied for ethical permission to
conduct the DiReCT study from the UK Health Research
Authority (HRA), for review by a National Research Eth-
ics Service Committee in order to determine if the HRA
would find the features of the cmRCT methodology eth-
ically acceptable, principally the ethics of seeking prior
consent from participants for future randomisation into
unspecified clinical trials. We developed our ethics ap-
plication and participant materials with input from a mem-
ber of a public and patient involvement (PPI) group for
depression: the Lived Experience Group at the University of
Exeter. We outlined procedures that sought three levels of
consent from participants: (1) to be contacted by researchers;
(2) to share their medical records with researchers; (3) to be
offered randomly allocated active treatment procedures in
future unspecified clinical trials. We applied for approval
through the web based ‘IRAS’ system through which all UK
clinical researchers must seek ethical clearance.
Phase II: the recruitment and trials test
In the second phase of the DiReCT study we tested the
yield of the cmRCT design in terms of the numbers of
participants with common mental health problems pre-
senting for treatment who consented to: (1) be contacted
by researchers; (2) share their medical records with re-
searchers; (3) be offered randomly allocated active treat-
ment procedures in future unspecified, and at this stage
hypothetical, clinical trials. We emphasised that agree-
ment to random selection would not infer consent to fu-
ture trial interventions, but merely consent to be offered
randomly selected active treatment procedures in future
unspecified clinical trials. At this stage our proposal to
participants would not include actual future trials. Potential
participants were informed that the DiReCTstudy was hypo-
thetical in nature as a feasibility proof-of-principle test of our
pre-randomisation consent procedures. At the time of test-
ing there were no trials running and participants were in-
formed that they would not be offered trial participation at
the time of the study or in the future as a consequence of
their participation in this initial feasibility test.
We used a three-stage consent process. In stage 1, all
new patients referred or self-referred to the study site
were posted a patient information sheet and consent
form with a compliments slip from the IAPT service
introducing the DiReCT study. In stage 2, cliniciansassessing and treating patients invited them verbally to
participate during one of their first two clinical appoint-
ments. Patients who indicated that they wished to par-
ticipate in the study signed a form consenting to one or
more of the three levels of participation. Clinicians were
instructed that they should seek to obtain consent from
all patients, but that it was acceptable to delay informa-
tion giving and the consent procedure for exceptionally
distressed patients until a later appointment. We also
collected blank consent forms for patients who declined
to participate, signed and dated by clinicians so that we
could measure the total number of patients who were
offered the opportunity to take part in the DiReCT
study by clinicians. No personal information was in-
cluded on declined consent forms. In stage 3, a mem-
ber of the research team contacted consenting patients
by telephone within 14 days of the participant giving
consent to verify their consent using the same three
levels as stage 2. All eventual participants included in
the study, therefore, gave informed consent at both
stages 2 and 3 before any data was collected or re-
corded by the research team. We allocated all such
consenting participants a unique ID number, recorded
all data on a case report form and stored it securely in
an anonymised database.
Phase III: clinical acceptability
After the phase II recruitment and trials test had been
completed, we undertook interviews with a purposive
sample of clinicians involved in the DiReCT study to in-
vestigate their views of recruiting and consenting partici-
pants. We sampled both PWPs and senior therapists,
purposively selecting those who had recruited either
small or large numbers of participants into the study. A
post-doctoral researcher, independent of the DiReCT
study team, unknown to the clinicians and experienced
in qualitative interviewing, approached clinicians directly
and carried out the interviews. All interviews were con-
ducted on the telephone whilst the respondent was in a
private space at his/her workplace. Interviews were planned
to take between 15 and 30 minutes, and were audio re-
corded and transcribed verbatim. The accuracy of tran-
scripts was checked by another member of the research
team before analysis. Interviews were structured using an a
priori defined topic guide to enquire about clinicians’ views
of having been involved in the recruitment and consent
procedure for the DiReCT study. All interviews started with
one overarching question: “Recently you were part of a re-
search study called ‘DiReCT’. During this study you were
to invite patients to enrol in the study, and if they agreed
to do so, to take their consent. Please tell us about your
experiences of doing this”. Additional probing questions
were used to help clinicians elaborate on their initial
descriptions.
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We recorded the total number of patients assessed and
treated by the service during the data collection period.
We recorded the number of consenting participants and
their consent levels along with the number of blank con-
sent forms signed by a therapist, indicating the number
of patients who declined to participate. We collected
routine demographic data on age, gender and employ-
ment status, and depression levels as measured by the
Patient Health Questionnaire-9 (PHQ-9) [22] for con-
senting participants from the IAPT service routine clin-
ical record database. We also obtained an anonymised
report of the same demographic and clinical variables
for the total patient population treated at the site during
the study period.
Analysis
We analysed the results of phase II using descriptive sta-
tistics to report: (1) the proportion of patients who were
offered participation in the DiReCT study compared to
the total number of patients assessed and treated at the
service; (2) the proportion of patients consenting to par-
ticipation at each level of consent compared to the
number offered participation; and (3) the proportion of
participants confirming consent to participate at each
level of consent compared to the number initially con-
senting at the same levels. We calculated the similarities
or differences between our sample and the total assessed
and treated population on age, gender, employment status
and PHQ-9 score using unpaired t-tests for continuous
variables and chi-square for dichotomous variables.
Members of our team, experienced and trained in
the analysis of qualitative data (DAR and SRos con-
ducted a descriptive analysis of interview transcripts
using a framework-guided thematic analysis [23]. We
began analysis with familiarisation of the text and used
our a priori topic guide to structure our initial descrip-
tive coding scheme to develop categories of meaning.
As concepts within these topics began to emerge, we
used constant comparison techniques and pattern cod-
ing to connect emergent categories and refine our cod-
ing framework. An experienced and independent third
member of the team (GB) oversaw and refined our
analysis and advised on the further analysis and pres-
entation of the qualitative data. We held regular meet-
ings between analysts to establish the trustworthiness
of the coding frame and thematic categories.
Results
Phase I: the ethics test
We obtained a favourable ethical opinion from the
HRA’s National Research Ethics Service Committee
East Midlands – Nottingham 1 Research Ethics Commit-
tee (REC) after receiving advice from the committee tosubmit for ‘Proportionate Review’. The Proportionate Re-
view Service receives applications from research studies
where the ethics committee believe that there is minimal
risk, burden or intrusion for research participants and
consequently applications are reviewed by a sub-committee
rather than at a full meeting of a REC. The process of
obtaining a favourable ethics opinion for the DiReCT study
took 2 weeks from submission by this process (Ref 12/EM/
0326). The sub-committee lead reviewer sought a tele-
phone conversation with the Chief Investigator to clarify
details of the application, during which there was an ac-
knowledgement by the reviewer of the importance of
improving trial recruitment, given that many ethics ex-
tension applications to RECs are a result of study re-
cruitment difficulties. The reviewer raised no concerns
about our intention to invite patients to pre-consent to
randomisation as part of our hypothetical feasibility
test, nor to the overall principle of our consent proce-
dures should trials actually be running in any future
cmRCT.
Phase II: the recruitment and trials test
Consent data
The clinical service assessed 1,240 people during the
4 months of the DiReCT study, of whom 752 were of-
fered treatment for depression and anxiety problems and
were thus eligible for participation. All 752 treated pa-
tients were posted study information in advance of their
first assessment. The clinical team obtained consent or
decline data from 131/752 (17%) of potential partici-
pants during the study period. Of these 131 people, 47
(36%) declined to participate. Of the remaining 84
(64%), all participants consented to be contacted by a
researcher, 83 consented to their medical records being
looked at by researchers, and 83 consented to being
randomised into future trials.
When contacted by the research team to confirm con-
sent, 71/84 (85%) of participants consented to having
their medical records included in research and 69/84
(82%) consented to be offered randomly allocated active
treatment procedures in future unspecified and at this
stage hypothetical clinical trials. Five out of 84 (6%)
people decided against participation and we were unable
to contact the remaining eight (10%).
Figure 1 summarises the flow of participant recruitment
where 71/752 (9%) of the total number of patients who
were offered treatment during the study period consented
to take part and 69/131 (53%) of all patients who were
invited by a clinician to take part consented to be offered
randomly allocated active treatment procedures.
Participant demographics
There were no differences between included participants
in age, gender, employment and depression severity
Figure 1 Recruitment flow diagram. cmRCT, cohort multiple randomised controlled trial.
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people treated by the service during the study period,
although there was a trend towards our included partici-
pants having a greater severity of depression.
Consent procedure
Twenty-one clinicians were involved in the initial con-
sent procedure: 14 senior therapists and seven PWPs.
Sixteen clinicians were full time and five part-time.
Table 2 details recruitment patterns by grade and hours
worked.
Qualitative interview data
We interviewed nine of the 21 clinicians who were in-
volved in the DiReCT study (four therapists and five
PWPs). All clinicians who were asked to take part in the
interviews consented. Our analysis aimed to describe the
views of clinicians about the process of routinely recruit-
ing and consenting patients into the DiReCT study. OurTable 1 Participant demographics
Study sample Clinical popula
n 71 752
Age (years; mean (SD)) 41.5 (15.6) 42.1 (15.4)
Gender F =48 (67.6%); M =23 (32.4%) F =452 (60.1%);
Employment status Employed: 38 (53.5%) Employed: 346
PHQ9 score (mean (SD)) 17.5 (5.3) 16 (6.3)
df, Degrees of freedom; F, female; M, male; n/a, not applicable; PHQ9, Patient Healtresults showed that their views could be understood in
terms of four themes: ‘working with patients takes prior-
ity’; ‘workplace systems and pressures of daily work’;
‘clinicians’ views of the DiReCT project and of research;
‘clinicians’ perception of patients’ reaction to the recruit-
ment process’.
Working with patients takes priority
The theme ‘working with patients takes priority’ describes
the difficulties clinicians could experience in balancing
their existing clinical practices with the recruitment
process for the DiReCT study. The theme covered both
their views on having to meet the patient’s needs in gen-
eral, especially those patients in great distress, together
with the importance clinicians ascribed to developing a
therapeutic relationship.
In terms of meeting patients’ needs, clinicians de-
scribed that they would only carry out the consent
procedure provided their clinical priorities had beention t value or chi square 95% CI P value
0.31 (df =821) −3.161 to 4.361 0.75
M =300 (39.9%) 1.47 (df =1) n/a 0.23
(46.0%) 1.42 (df =1) n/a 0.24
1.94 (df =821) −3.017 to 0.017 0.053
h Questionnaire-9.
Table 2 Number of consent or decline forms returned by
clinician type
n Mean (SD) t value 95% CI P value
PWPs 7 12.9 (7.6) 3.36 4.21 to 15.99 0.013
Therapists 14 2.8 (3.3)
Full time 16 6.9 (7.5) 0.92 −3.30 to 9.10 0.379
Part time 5 4 (5.7)
All 21 6.2 (7.1)
PWP, Psychological Wellbeing Practitioners.
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patients’ immediate mental health needs. Introducing
the DiReCT study was described as getting in the way
of devising a treatment plan and delivering the therapy.
Treating the patient's problems was viewed as a greater
priority for clinicians than inviting them to take part in
this study. They described having to make prioritisa-
tion decisions on when to introduce the topic of
research participation - for example, at the second
appointment when patients could be less anxious or
even at a later appointment when clinicians were moni-
toring patient progress rather than introducing new clin-
ical techniques.
“I was constantly trying to weigh up, you know,
should I let this go or, what’s in the patient’s interest
in this case? Should I pursue it or, let that go and
focus more on the treatment and coming up with the
rest of the plan?” (PWP 5)“I think a lot of the time it was very, very difficult to
do it… see, it was easier to perhaps broach it right at
the beginning at the assessment, or, umm after you’ve
had a few sessions because then, there was less going
on”. (PWP 2)
In some cases clinicians described how they had to
support patients who were in distress as the major focus
of their sessional work for these patients. This was
particularly the case when clinicians were interviewing
patients in great distress, where the focus of their clinical
work was very clearly directed towards responding to
and helping the patient manage their distress. Introdu-
cing the study to distressed patients was described as
making the clinicians feel uncomfortable. One clinician
explained it as:
“I think… if someone is extremely distressed then…
it’s not the first priority at that point when someone
is in distress or upset… it wouldn’t feel comfortable at
the end of an appointment that had been clearly very
emotionally difficult for a patient to say, ‘Oh and bythe way, can I just have a talk to you about this whole
other thing”. (PWP 4)
Furthermore, in this theme the clinicians described the
importance of the therapeutic relationship between them-
selves and patients. They expressed concern that introdu-
cing the DiReCT study would get in the way of developing
this relationship, particularly at the early stages of their
therapeutic work with patients.
“Having another element, right at the key point
when you’re doing that relationship building with
people… and you already feel like you’re not
getting enough time to talk to them about what’s
bringing them, and how they’re feeling at times…”
(Therapist 1)
Workplace systems and pressures of daily work
The theme ‘workplace systems and pressures of daily
work’ describes the experience of organisational preroga-
tives on clinicians’ daily work and how this affected their
ability to recruit patients into the DiReCT study. This
theme covered descriptions of workload targets and
resulting time pressures, clinical roles in the team and
administrative systems.
In regards to workload targets and resulting time pres-
sures, clinicians described how high volumes of patients
and short appointment times could make it difficult to
fit the recruitment procedure into an appointment. One
of the issues described in this theme was the clinicians’
concern over how to find the time they believed they
needed in order to participate in the process of recruit-
ing and consenting patients into the study. As one
clinician expressed it:
“We’re so pressured with targets to get, you know,
see so many people a week… and have 30 minute
sessions, and then it’s sort of one after the other,
you’ve barely got time between each session to even
reflect. That adding anything else onto it… was very
pressured.” (PWP 2)
Clinicians’ description of the recruitment process also
included their views on the roles and responsibilities of
different clinicians in the team. When it came to de-
scribing this, senior clinicians in a ‘high-intensity’ ther-
apy role outlined how difficult it could be for them to
recruit patients during the first few appointments, as
they described being less familiar with this assessment
role, ordinarily undertaken by PWPs. At times, because
of staff shortages, senior therapists provided substitute
cover for PWPs. In these circumstances, they described
how not consistently seeing the same patients at follow
up appointments could make it difficult to carry out the
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during the first appointment.
“Because we have an issue with the high attrition [of
PWP’s], we’ve had a lot of [senior therapists] doing
assessments, then put them on the waiting list for a
PWP to pick up… so when the PWP picks up the
person it might be a month between the assessment
and the follow up, so they’ve got to… check the
problem statement’s the same… and it’s a bit of a mini
reassessment, so that takes time… they’ve also got to
start some therapy, and then they’ve got to spend
eight minutes going through the study… they were
struggling to get all that in”. (Therapist 3)
Furthermore, within this theme of workplace systems
and pressures of daily work, clinicians reported that the
impact of different working conditions could in their
view impede their ability to fit the recruitment and con-
sent procedure into their appointments. For example,
they described how a lack of equipment and record
keeping systems could make it difficult to remember to
invite patients to take part in the study.
“We had this, umm, additional new clinical space that
they’d purchased for us upstairs, they didn’t have any
IT and didn’t have any phones… so actually… what
happened with that was it made it quite difficult… to
err, remember when somebody was on their second
or third or fourth session that was quite tricky…. and
that meant that sometimes people were missed”.
(PWP 5)
Clinicians’ views of the DiReCT project and of research
In the theme ‘clinicians’ views of the DiReCT project
and of research’ the way clinicians viewed both research
procedures specific to the DiReCT study and their per-
ceptions of research in general were reflected.
In terms of clinicians’ experiences of the DiReCT pro-
ject, they described how the complexity of the DiReCT
recruitment and consent process and the amount of
paperwork required could make it difficult for them to
present the study to patients, and that having less of a
role in the procedure would have been easier for them.
It was felt by some clinicians that researchers should
carry out informed consent and that clinicians should
only have a limited role - for example, in collecting ‘con-
sent to contact researcher’ forms from patients. A less
involved role might have persuaded clinicians to ap-
proach more patients. The hypothetical and pilot nature
of the DiReCT study was also viewed as a reason why
clinicians might choose not to try and recruit some pa-
tients, given that recruiting patients would confer no
tangible benefits to their patients.“I’d have been quite happy for someone to ask people,
you know, to bring me something and if they bring it
to me, just tick say, ‘I’m interested in more
information on this, but I’m not signing up to
anything right now’… I’d be quite happy for that and
then let the research team talk about it with them or
something because they know what’s going on better
than I do… so it’s just a little bit more streamlined so
we have less of a role in terms of explaining”. (PWP 1)“As far as I was aware it was almost like a pre-test to,
pre-research so it wasn’t actually kind of… as far as I
was aware it wasn’t actually counted towards anything
so again it was a bit confusing”. (Therapist 4)
Clinicians described generally positive attitudes to re-
search and how having experience of research in general
could contribute to a positive attitude to the DiReCT
study. Again, this could reflect the way that clinicians
viewed their role in research, in this case a more general
attitude to research per se. Having a background in re-
search was described as being useful in helping clinicians
feel more competent in carrying out the procedure,
which some clinicians viewed as getting easier with prac-
tice. A positive aspect of the DiReCT study was that it
was viewed as possibly helping to contribute to future
quality research, which was described as important.
“There were some things which I had liked about it
because I do think it is important that we get umm…
you know, umm… lots of people to make really
robust, umm… research papers written umm but, so
that was the good bit, that was me, sort of quite liking
that aspect of it”. (PWP 1)
‘Clinicians’ perception of patients’ reaction to the
recruitment process’
The theme ‘clinicians’ perception of patients’ reaction to
the recruitment process’ contained descriptions around
how patients reacted when the clinicians approached
them in regards to the recruitment and consent process.
The theme also covered ethical concerns around the val-
idity of consent consequent upon interpersonal interac-
tions reported by clinicians.
Clinicians described how it could be more difficult to
recruit certain patients. They were less likely to invite
patients to participate in the DiReCT study if he or she
displayed characteristics, views or behaviours that were
viewed as not conducive to the recruitment and consent
procedure. One clinician described it as:
“We have a bit of an issue with err, angry men… so,
umm who, we’ll have some people who come in quite
angry and they don’t want to fill the MDS in so, if
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they’re quite confrontational… then we’re not going
say ‘well can you fill-, can I spend eight minutes to
discuss this with you as well?’” (Therapist 3)
In this theme the clinicians additionally described that
there was a distinct divide in attitude between those pa-
tients who were willing to consent and those who were
not willing. Clinicians described how they were more
likely to follow through the recruitment process with
patients who showed an apparently positive attitude to
the study already. For example, some patients would
attend appointments having made their decision to
participate in the DiReCT study prior to attending their
assessment, in that they brought the consent form
already signed to their first appointment.
“Yeah the people, that was quite distinctly the people
that, umm, did want to do it, it was quite obvious, the
people that did… their view was ‘Ooh yes, we need
something like this, I’ve read it through, and’ …oh
yeah, I mean the people that wanted to do it had read
it all the way through, the people that didn’t want to
do it, a few of them had read it through and didn’t see
the point, and a few of the others had been put off by
it and sort of thought ‘I don’t wanna do this”. (PWP 3)
Patient characteristics as perceived by clinicians also
affected their decisions over whether to offer participa-
tion - for example, low levels of patient literacy which
could lead clinicians to doubt patient comprehension.
Clinicians also reported their perception that those pa-
tients with more severe depression were less likely to
consent to participation. Some clinicians described feel-
ing confused about the eligibility of newly referred pa-
tients who wanted to take part but were not eligible for
treatment by the service.
“It was quite tricky when… if they’d received it in the
post and they had got enthusiastic about it but then I’d
deemed them not suitable, because they weren’t suitable
for our service, that was a bit difficult”. (PWP 5)
The ethical concerns perceived by the clinicians were
mainly described as reflecting the validity of consent
consequent upon interpersonal interactions between cli-
nicians and patients. Descriptions covered how the clini-
cians questioned the validity of consent from patients
who did not appear to fully understand the DiReCT
study. It could become apparent for the clinicians that
the patients had signed the consent form without fully
reading the patient information sheet. One clinician de-
scribed it as: “I mean ‘fully understood’ is pushing it in
some cases, I mean some of them told me they hadn’tread it, they’d just signed it” (PWP 1). These kinds of
situations were described as making the clinicians feel
uncomfortable about forwarding their consent forms to
the research team.
“I had a couple of people that… had come in, signed it
all and I just kind of checked it out and they said
‘Oh I just signed it, I don’t really care, you know I just
want to get on with this’… so I wasn’t quite sure what
to do with that really that they’d signed it, they said
‘yes I’m consenting’, but… when I’d come to explain
the bit about the study, they really weren’t interested”.
(Therapist 3)
Further, the theme also represented descriptions con-
cerning the interpersonal relationship dynamic between
the clinician and patient, where the clinicians perceived
that they were unintentionally endorsing the DiReCT
study to the patients. Clinicians also described how the
power dynamic within the therapeutic relationship could
make discussing the study with patients make them feel
uncomfortable.
“I was also concerned as well about the kind of the,
power aspect of the relationship as well you know,
I was awfully aware that, you know, with the best will
in the world, we always try not to be in a position of
power, that’s part of the role but, you are… umm and
asking someone to go away and read this thing,
explaining… why it’s important or why it’s being
done… you’re kind of, endorsing it, you’re kind of
saying this is something that’s good, ‘it’s your choice’
but ‘it’s good’… and it just, it feels a little
uncomfortable”. (PWP 1)
Discussion
We found that more than 50% of patients in a routine
UK NHS anxiety and depression service would consent
to become part of a cohort within which they could be
randomly selected to receive future unspecified treat-
ments in clinical trials, a research design that was
acceptable to a UK ethics committee. The acceptability
of the cmRCT system to clinicians was influenced by
their clinical concerns for patient wellbeing, pressures of
work, their views of both general research and the
specific DiReCT study, and how they viewed patients’
responses to being offered participation in the study.
In the UK at least, ethics committees are prepared to
agree to a system where only those people randomised
to active trial arms are subsequently approached by re-
searchers, and where those in the control group are not
informed about their trial participation. We have repli-
cated the result of a previous favourable ethical opinion
[20] that the cmRCT – a form of modified Zelen design
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into the standard RCT design where all participants are
approached for specific trial consent. In our application
of the cmRCT principles, participants were pre-warned
about the possibility of random selection and asked to
consent, albeit to unspecified experimental treatments,
before being included in the cohort. Our DiReCT study
recruitment and consent procedures may, therefore,
address some ethical reservations about the original
Zelen design.
Our results for our recruitment and trials tests, re-
garding the willingness of patients in a routine health
care setting to agree to both inclusion in a cohort and to
be randomly selected for trial treatments, are very en-
couraging. All but two of our recruited participants were
willing to be enrolled in both the cohort itself and ran-
dom selection. As a consequence, we might predict that
if it was standard practice to offer all patients suffering
from common mental health disorders the opportunity
to participate in future unspecified clinical trials, around
50% of patients would consent to participate in both the
cohort and future trials. By consenting to both cohort
membership and trial participation, patients were agree-
ing to provide data as part of a potential control group
for trials, without further consent being required. In pre-
vious trials we have found that, when identifying and ap-
proaching potential participants directly after screening
patient records, only around 10% of potentially eligible
people are subsequently randomised [24]. Thus, the
cmRCT may present a method of maximising partici-
pant recruitment that could be around five times more
efficient than alternatives. One might also argue that tri-
als that recruit 50% of potentially eligible participants
are likely to produce results that are more generalisable
to the clinical population under study.
Less encouraging was the fact that clinicians held re-
cruitment and consent discussions with only 17% of po-
tentially eligible participants. Indeed, other commentators
[9,14] have noted that a major barrier to participant re-
cruitment is clinician, not patient, reluctance to engage in
the research recruitment process. The results from our
analysis of clinician interviews help to explain our descrip-
tive statistical analyses. Our clinicians described a range of
factors that could influence their decision-making, includ-
ing their prioritisation of patient care, the practical diffi-
culties of finding time to engage with patients about
research, their own views about the research process itself
and how patients responded when asked to participate.
Some clinicians experienced a conflict between their re-
search recruitment responsibilities and the need to estab-
lish a therapeutic relationship and care for distressed
patients, a finding echoing previous studies [11,25,26].
Overlaying these interpersonal concerns were organisa-
tional difficulties including the pressures of work, whereinclinicians had multiple clinical and administrative jobs to
do within the context of a highly pressured environment,
once again an issue described in other studies [11]. The
hypothetical nature of the DiReCT study was cited as a
reason not to engage in recruitment as was the need to
offer complex research design explanations.
Strengths and limitations
Our DiReCT study was hypothetical in nature. We did
not have any trials running in a cmRCT system at the
time we undertook this feasibility study. Therefore, we
are unable to report the conversion rate of those partici-
pants who agreed to be part of the pre-randomisation
consenting cohort and those who would subsequently
actually consent to the offer of an experimental inter-
vention. It is conceivable that some of our DiReCT
cohort might turn down the offer of treatment once
it was made concrete. Conversely, our yield might
have been higher if trials had been running, given the
reticence of some clinicians to offer patients the op-
portunity to participate in what was only a hypothet-
ical exercise in this instance, and the unknown number of
patients who might have declined participation for the
same reason.
Our data is reliant on clinician self-report. We had no
way of verifying if the numbers of blank consent forms
returned represented the true number of participants
who were offered and then declined participation. It
might be that we have over-estimated the proportion of
participants who would consent to be part of a cmRCT
system once they are asked by a clinician, since it might
be that some participants were asked but that clinicians
did not return a blank form. However, a 50% participa-
tion rate is not unusual in previously reported studies
[27,28] lending credence to our observations.
Our study was small, particularly in terms of the num-
bers of clinicians interviewed, a limitation on the find-
ings from our interview analysis. Although we would
urge caution in accepting our interview data as general-
isable to other clinical teams, there have been similar
views reported in several other studies [9,25]. It is cer-
tainly possible that our analytical themes will be relevant
beyond our specific contextual environment, but replica-
tion elsewhere should be undertaken. Furthermore, we
did not collect qualitative interview data from partici-
pants, which may have given us further insights into the
acceptability of the cmRCT design from the perspective
of potential patient participants.
Implications
The implications of the DiReCT study are two-fold.
Firstly, despite the fact that our study was hypothetical
and that there was no direct benefit to participants,
more than 50% of patients approached consented to
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a conservative estimate of the potential cmRCT yield if
trials were actually recruiting. We also suggest that the
diagnoses of patients might not have a serious impact on
the system yield, given that in UK cancer services 64% of
patients who were approached to take part in research
subsequently went on to do so [29], only slightly more
than in our community mental health environment. As
noted by the originators of the cmRCT model [3], the
cmRCT system could provide a ready-made pool of
research participants already having consented to the
offer of trial treatments. Trialist and health care pro-
viders would then avoid the need to set up new recruit-
ment procedures each time a trial was initiated in the
same health care environment.
Secondly, it is clear that engaging clinicians in the
research process is both difficult and yet as equally im-
portant as the not inconsiderable efforts being made to
improve PPI in research, particularly in the UK, where
extensive PPI is a prerequisite for NIHR project funding.
Clinicians gave us multiple, sometimes contradictory, expla-
nations for their recruitment behaviours. For example, one
finding from our qualitative data was that clinicians did not
have a consistent view on how much they should be respon-
sible for collecting informed consent from their patients.
Some clinicians suggested confining themselves to merely
recruiting patients for contact with researchers, and that
researchers should explain the nature of the research being
proposed, effectively shifting responsibility for study recruit-
ment from clinicians to researchers. Indeed, such a system of
‘consent for consent’ (for example, http://www.slam.nhs.uk/
research/patient-involvement/current-opportunities/consent-
for-contact) is a feature of some research active health care
providers’ activities. However, other clinicians wanted to
assure themselves that patients truly understood what they
were consenting to, before being willing to co-sign consent
forms. In contrast, pressure of work and clinical focus were
more universal explanations offered by clinicians to explain
their difficulties recruiting participants.
Clearly, health care providers could consider embed-
ding a cmRCT system in their routine clinical proce-
dures as one method to address the findings of a recent
report that suggested many health care providers are not
orientated towards research participant recruitment [30].
However, multiple efforts are likely to be required to en-
gage many clinicians. One possibility suggested by Donovan
and colleagues [11] is for more support and training of cli-
nicians. However, this may be insufficient in of itself, and
a more comprehensive implementation model might be
required, including attention to individual clinician, organ-
isational and informational factors. One such model, the
Normalisation Process Theory [31], proposes that in order
to embed new procedures in routine practice efforts have
to be made to enable all concerned to make sense of thenew system (‘coherence’), build and sustain a community
of practice around it (‘cognitive participation’), under-
take the operational work to enact a set of new prac-
tices (‘collective action’), and appraise the work that
people do to assess and understand the ways that a
new set of practices affect them and others around
them (‘reflexive monitoring’). It is likely that such the-
oretically underpinned and sophisticated implementation
procedures will be required before the recruitment of
participants into research cohorts becomes embedded in
routine practice, given that the research community has
been reporting these difficulties for many, many years [25].
Conclusion
The cmRCT system offers the potential to improve the ef-
ficiency of recruitment into clinical trials and is acceptable
ethically and to many patients. Nonetheless, overcoming
the multiple factors driving the difficulties clinicians ex-
perience in patient recruitment more generally is likely
to require the application of significant implementa-
tion science-informed effort.
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